If some of the customers are in this group -insurers,Hmo's,etc--then we should expect to see some results in sales--If they are still prospective--then lets hope they can bring some around..
Printable View
I think you will find if you actually bother to check Steve that clinical trials really were completed nearly two years ago with absolutely exceptional results, and those trial results were independently peer reviewed in 2012 to the satisfaction of those clinicians involved.
What you may also like to consider is the very many successful LDT companies that are operating in the US and have been so for a long time, probably hundreds, routinely and professionally delivering diagnostic tests to the health sector across the entire range of medical disciplines.
But of course, perhaps you are right and all those companies and their professionals are wrong, I don't really think time needs to tell, or perhaps all those companies will now suddenly have to disappear in a puff of sharetrader forum logic.
Forbarr up grading PEB to $1.25 forecast from $1.10. Why they are doing this right before a critical HY report is beyond me. They're either goung to be very right or very wrong very soon!
You been chucking them your spreadsheets then MAC??? :D
Ha, would be interested in a link if you have one actually.
Given Forbar have taken such a conservative approach thus far with PEB, we should be watching for a series of upgrades over the coming year or two, and they did pretty much tell us that within their report in their own way, but yes I agree there is a risk they might be embarrassed at some point through discounting valuations too much, Morningstar are possibly the best at embarrassing themselves in that way.
Downramp when not holding and ramp up when holding, isnt that how it works? Lol. Nah I want it to stay cheap so I can buy in cheaply.
The only ramping in either direction tends to come from short termers, long termers just don’t care much for sentiment at all really, it’s research and valuation that matters in the long run.
There is plenty of room though within the sensitivity analysis, within the valuation range of the Edison report, $0.42 to $3.57, for a range of views.
However, when considering analysts valuations one must also consider the level of conservatism provided, Edison have this to say about that valuation range;
“We consider the chief variables are the level of market penetration that can be achieved, particularly in the US, and average pricing. Our base case is on the conservative side in both regards, therefore we expect significant upside potential on our forecasts if Pacific Edge’s performance exceeds our cautious expectations”
Forbar, and with no disrespect to Chelsea who has captured the essence and potential of Pacific Edge very well, tend also to be conservative.
They don’t cover a lot of pre-profitable stocks and they must feel a need to be very conservative in consideration of the interests of their cliental, many of whom do not have the time or FA ability to do their own analysis.
I forsee a lot of upgrades over the next one to two years as that conservatism relaxes. It may even be that Forbar intend to incrementally step-up the expectation of their cliental gradually rather than providing a valuation matched to the goals of Pacific Edge, perhaps that is even best as it assists in taking the volatility out, but for those who do their own work, the opportunity may be more apparent.